The cost-effectiveness of metformin in pre-diabetics: a systematic literature review of health economic evaluations

References

• Bhattarai MD. Three patterns of rising type 2 diabetes prevalence in the world: need to widen the concept of prevention in individuals into control in the community. JNMA J Nepal Med Assoc. 2009;48(174):173–179.
   PubMedGoogle Scholar
• Hawley NL, McGarvey ST. Obesity and diabetes in Pacific Islanders: the current burden and the need for urgent action. Curr Diab Rep. 2015;15(5):29.
   PubMed Web of Science ®Google Scholar
• Li H, Oldenburg B, Chamberlain C, et al. Diabetes prevalence and determinants in adults in China mainland from 2000 to 2010: a systematic review. Diabetes Res Clin Pract. 2012;98(2):226–235.
   PubMed Web of Science ®Google Scholar
• Evans JM, Barnett KN, Ogston SA, et al. Increasing prevalence of type 2 diabetes in a Scottish population: effect of increasing incidence or decreasing mortality? Diabetologia. 2007;50(4):729–732.
   PubMed Web of Science ®Google Scholar
• Gujral UP, Echouffo-Tcheugui JB, Narayan K. Commentary: trends in prevalence of type 2 diabetes and prediabetes in South Asians–does it tell a story? Int J Epidemiol. 2011;40(6):1554–1555.
   PubMed Web of Science ®Google Scholar
• Lipscombe LL, Hux JE. Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995–2005: a population-based study. Lancet. 2007;369(9563):750–756.
   PubMed Web of Science ®Google Scholar
• Monesi L, Baviera M, Marzona I, et al. Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population-based study. Diabet Med. 2012;29(3):385–392.
   PubMed Web of Science ®Google Scholar
• Thibault V, Belanger M, LeBlanc E, et al. Factors that could explain the increasing prevalence of type 2 diabetes among adults in a Canadian province: a critical review and analysis. Diabetol Metab Syndr. 2016;8:71.
   PubMed Web of Science ®Google Scholar
• Satman I, Omer B, Tutuncu Y, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 2013;28(2):169–180.
   PubMed Web of Science ®Google Scholar
• Smith JP. Nature and causes of trends in male diabetes prevalence, undiagnosed diabetes, and the socioeconomic status health gradient. Proc Natl Acad Sci U S A. 2007;104(33):13225–13231.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang Y, Huang ES. Changes in racial/ethnic disparities in the prevalence of Type 2 diabetes by obesity level among US adults. Ethn Health. 2009;14(5):439–457.
   PubMed Web of Science ®Google Scholar
• Li MZ, Su L, Liang BY, et al. Trends in prevalence, awareness, treatment, and control of diabetes mellitus in mainland china from 1979 to 2012. Int J Endocrinol. 2013;2013:753150.
   PubMed Web of Science ®Google Scholar
• Jan Mohamed HJ, Yap RW, Loy SL, et al. Prevalence and determinants of overweight, obesity, and type 2 diabetes mellitus in adults in Malaysia. Asia Pac J Public Health. 2015;27(2):123–135.
   PubMed Web of Science ®Google Scholar
• Menke A, Rust KF, Fradkin J, et al. Associations between trends in race/ethnicity, aging, and body mass index with diabetes prevalence in the United States: a series of cross-sectional studies. Ann Intern Med. 2014;161(5):328–335.
   PubMed Web of Science ®Google Scholar
• Oggioni C, Lara J, Wells JC, et al. Shifts in population dietary patterns and physical inactivity as determinants of global trends in the prevalence of diabetes: an ecological analysis. Nutr Metab Cardiovasc Dis. 2014;24(10):1105–1111.
   PubMed Web of Science ®Google Scholar
• Saidi O, O’Flaherty M, Mansour NB, et al. Forecasting Tunisian type 2 diabetes prevalence to 2027: validation of a simple model. BMC Public Health. 2015;15:104.
   PubMed Web of Science ®Google Scholar
• Risk Factor NCD. Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–1530.
   PubMed Web of Science ®Google Scholar
• Collins AJ, Foley RN, Gilbertson DT, et al. United States renal data system public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl. 2015;5(1):2–7.
   PubMed Web of Science ®Google Scholar
• Moxey PW, Gogalniceanu P, Hinchliffe RJ, et al. Lower extremity amputations–a review of global variability in incidence. Diabet Med. 2011;28(10):1144–1153.
   PubMed Web of Science ®Google Scholar
• Sobel BE, Schneider DJ. Cardiovascular complications in diabetes mellitus. Curr Opin Pharmacol. 2005;5(2):143–148.
   PubMed Web of Science ®Google Scholar
• Muka T, Imo D, Jaspers L, et al. The global impact of non-communicable diseases on healthcare spending and national income: a systematic review. Eur J Epidemiol. 2015;30(4):251–277.
   PubMed Web of Science ®Google Scholar
• Dieleman JL, Baral R, Birger M, et al. US spending on personal health care and public health, 1996–2013. Jama. 2016;316(24):2627–2646.
   PubMed Web of Science ®Google Scholar
• Bahia LR, Araujo DV, Schaan BD, et al. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system. Value Health. 2011;14(5 Suppl 1):S137–40.
   PubMed Web of Science ®Google Scholar
• Arredondo A, De Icaza E. The cost of diabetes in Latin America: evidence from Mexico. Value Health. 2011;14(5 Suppl 1):S85–8.
   PubMedGoogle Scholar
• Yesudian CA, Grepstad M, Visintin E, et al. The economic burden of diabetes in India: a review of the literature. Global Health. 2014;10:80.
   PubMed Web of Science ®Google Scholar
• World Health Organisation (WHO). Global report on diabetes. France: WHO Press; 2016.
   Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
   PubMed Web of Science ®Google Scholar
• Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009;374(9702):1677–1686.
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–297.
   PubMed Web of Science ®Google Scholar
• Li CL, Pan CY, Lu JM, et al. Effect of metformin on patients with impaired glucose tolerance. Diabet Med. 1999;16(6):477–481.
   PubMed Web of Science ®Google Scholar
• Wenying Y, Lixiang L, Jinwu Q. The preventive effect of Acarbose and Metformin on the IGT population from becoming diabetes mellitus: a 3-year multicentral prospective study. Chin Med J. 2001;114(9):920–920.
   Google Scholar
• Drummond ME, Sculpher MJ, Torrance GW, et al. Methods of economic evaluation of health care programmes, 3rd. Oxford University Press. 2005:48–51, Chp.3.
   Google Scholar
• Li R, Zhang P, Barker LE, et al. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33(8):1872–1894.
   PubMed Web of Science ®Google Scholar
• Li R, Zhang P. Cost-effectiveness of primary prevention of type 2 diabetes: an update of systemetic review. Diabetes. 2013;62:A325.
   Web of Science ®Google Scholar
• Alouki K, Delisle H, Bermudez-Tamayo C, et al. Lifestyle interventions to prevent Type 2 diabetes: a systematic review of economic evaluation studies. J Diabetes Res. 2016;2016:2159890.
   PubMedGoogle Scholar
• Roberts S, Barry E, Craig D, et al. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open. 2017;7(11):e017184.
   PubMed Web of Science ®Google Scholar
• Glechner A, Keuchel L, Affengruber L, et al. Effects of lifestyle changes on adults with prediabetes: A systematic review and meta-analysis. Prim Care Diabetes. 2018;12(5):393–408.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26(9):2518–2523.
   PubMed Web of Science ®Google Scholar
• Png ME, Yoong JS, Petta S. Evaluating the cost-effectiveness of lifestyle modification versus metformin therapy for the prevention of diabetes in Singapore. PloS One. 2014;9(9):e107225.
   PubMed Web of Science ®Google Scholar
• Ramachandran A, Snehalatha C, Yamuna A, et al. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care. 2007;30(10):2548–2552.
   PubMed Web of Science ®Google Scholar
• Bertram MY, Lim SS, Barendregt JJ, et al. Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia. 2010;53(5):875–881.
   PubMed Web of Science ®Google Scholar
• Icks A, Rathmann W, Haastert B, et al. Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a ‘real world’ routine healthcare setting: model based on the KORA Survey 2000. Diabet Med. 2007;24(5):473–480.
   PubMed Web of Science ®Google Scholar
• Schaufler TM, Wolff M. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany. Appl Health Econ Health Policy. 2010;8(3):191–202.
   PubMedGoogle Scholar
• Caro JJ, Getsios D, Caro I, et al. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada. Diabet Med. 2004;21(11):1229–1236.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35(4):723–730.
   PubMed Web of Science ®Google Scholar
• Herman WH, Edelstein SL, Ratner RE, et al. Effectiveness and cost-effectiveness of diabetes prevention among adherent participants. Am J Manag Care. 2013;19(3):194–202.
   PubMed Web of Science ®Google Scholar
• Herman WH, Hoerger TJ, Brandle M, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142(5):323–332.
   PubMed Web of Science ®Google Scholar
• Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143(4):251–264.
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Cost-effectiveness analysis of the diabetes prevention program in a Spanish setting. Value Health J. 2004 Nov–Dec;7(6):741.
   Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther. 2004;26(2):304–321.
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Tucker DM. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis. Prim Care Diabetes. 2012;6(2):109–121.
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Comte S, et al. Intensive lifestyle changes or metformin in overweight, glucose intolerant patients: modeling the long-term health economics implications of the diabetes prevention program in the French, German, and UK. Value Health. 2002;PDB3.
   Web of Science ®Google Scholar
• Mantovani LG, Palmer AJ, Morgutt M, et al. Long-term cost-effectiveness of the Diabetes Prevention Program in an Italian setting. 40th EASD Annual Meeting of the European Association for the Study of Diabetes. Munich, Germany; 2004 Sep 5–9.
   Google Scholar
• Roberts S, Craig D, Adler A, et al. Economic evaluation of type 2 diabetes prevention programmes: markov model of low- and high-intensity lifestyle programmes and metformin in participants with different categories of intermediate hyperglycaemia. BMC Med. 2018;16(1):16.
   PubMed Web of Science ®Google Scholar
• Alolayan S, Eguale T, Segal A, et al. Can accounting for missing data cast doubt on previous conclusions reevaluating a 10 year cost-effectiveness analysis (cea) of the diabetes prevention program outcomes study (dpp/dppos)? Value in Health. 2018;21:S374.
   Web of Science ®Google Scholar
• Alolayan S, Eguale T, Segal A, et al. A 10 Year Cost-Effectiveness Analysis (Cea) Of The Diabetes Prevention Program Outcomes Study (Dpp/Dppos): clarifying the previous confusion. Value in Health. 2018;21:S133.
   Web of Science ®Google Scholar
• Alolayan S, Eguale T, Segal A, et al. Re-Analysis Of The Diabetes Prevention Program (Dpp) 3 year Cost-Effectiveness Analysis (Cea) using identical data but proper qaly calculations may revive its metformin conclusions. Value in Health. 2018;21:S132.
   Web of Science ®Google Scholar
• Alolayan S, Eguale T, Segal A, et al. Heterogeneity of treatment effect in the diabetes prevention program: high baseline risk of developing diabetes may provide a place for metformin in diabetes prevention that using overall sample average costs and effects conceals. Value Health. 2018;21:S132–S3.
   Web of Science ®Google Scholar
• Alfraih A, Rittenhouse B. Calculating appropriate ICERs in diabetes prevention program (DPP) cost-effectiveness and overturning misleading conclusions regarding optimal treatment. Value in Health. 2018;21:S75.
   Web of Science ®Google Scholar
• Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;75(10):1071–1094.
   PubMed Web of Science ®Google Scholar
• Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25(11):2958–2971.
   PubMed Web of Science ®Google Scholar
• Bhansali A, Masoodi SR. Efficacy of once- or twice-daily extended release metformin compared with thrice-daily immediate release metformin in type 2 diabetes mellitus. J Assoc Physicians India. 2005;53:441–445.
   PubMedGoogle Scholar
• Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab. 2009;11(4):338–342.
   PubMed Web of Science ®Google Scholar
• Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther. 2003;25(2):515–529.
   PubMed Web of Science ®Google Scholar
• Hsieh CH, He CT, Lee CH, et al. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. Metabolism. 2007;56(8):1087–1092.
   PubMed Web of Science ®Google Scholar
• Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2010;2:16.
   PubMed Web of Science ®Google Scholar
• Penning-van BFJ, van der Bij S, Erkens JA, et al. Effect of non-persistent use of oral glucose-lowering drugs on HbA1c goal attainment. Curr Med Res Opin. 2008;24(9):2523–2529.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Fonseca V, Berner B, et al. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006;29(4):759–764.
   PubMed Web of Science ®Google Scholar
• Alsultan M, Al-Omar H, Vandewalle B, et al. Metformin extended versus immediate release in Saudi Arabia: a costeffectiveness analysis. Glasgow: Value in Health; 2017;20(9).
   Google Scholar
• Fujii RK, Restrepo M, Fernandes RA, et al. Cost-effectiveness analysis and budget impact of an extended versus immediate release formulation of metformin In Type-2 diabetes mellitus treatment, from the perspective of the Brazilian public health system. Value Health. 2015;18(3).
   Web of Science ®Google Scholar
• Tsai AG, Wadden TA. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann Intern Med. 2005;142(1):56–66.
   PubMed Web of Science ®Google Scholar
• Gillett M, Royle P, Snaith A, et al. Non-pharmacological interventions to reduce the risk of diabetes in people with impaired glucose regulation: a systematic review and economic evaluation. Health Technol Assess. 2012;16(33):1–236, iii-iv.
   PubMed Web of Science ®Google Scholar